Thrombin receptor-dependent prostaglandin E2 synthesis in hamster fibroblasts: synergistic interactions with interleukin-1beta.
Cellular responses to alpha-thrombin are mediated through a G-protein-coupled receptor that undergoes proteolytic cleavage, unveiling a tethered peptide ligand with the amino-terminal sequence SFLLRN. The synthetic peptide SFLLRN can mimic many of thrombin's actions via directly stimulating the thrombin receptor. Thrombin has been implicated in several cellular events associated with tissue injury, including fibroblast growth, matrix deposition, and inflammatory responses. The role of the thrombin receptor in fibroblast-dependent release of the inflammatory mediator prostaglandin E2 was evaluated and compared to its well-characterized effect on cell proliferation. Both thrombin and SFLLRN stimulated [3H]thymidine incorporation into DNA but failed to induce prostaglandin E2 release from CCL39 cells. The inflammatory cytokine interleukin-1beta synergized with thrombin and SFLLRN to induce the release of prostaglandin E2, whereas it had no effect on thrombin receptor-mediated DNA synthesis. Interleukin-1beta had no direct effects on thrombin receptor-mediated phosphoinositide hydrolysis, suggesting that its effects were downstream from early signal transduction events. Thrombin and interleukin-1beta together significantly increased the expression of prostaglandin H synthase-2 in accordance with the prostaglandin E2 results. These studies indicate that the fibroblast thrombin receptor differentially couples to intracellular signaling pathways leading to distinct functional responses and that thrombin receptor-effector interactions could be modulated by interleukin-1beta.
Derian
C K
CK
Drug Discovery, The R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477, USA.
Eckardt
A J
AJ
D000818:Animals; D000991:Antithrombins / Q000494:pharmacology; D001120:Arginine / Q000031:analogs & derivatives; D006224:Cricetinae; D051546:Cyclooxygenase 2; D015232:Dinoprostone / Q000096:biosynthesis*; D004357:Drug Synergism; D005347:Fibroblasts / Q000187:drug effects*; D006868:Hydrolysis; D007375:Interleukin-1 / Q000494:pharmacology*; D007527:Isoenzymes / Q000096:biosynthesis; D010446:Peptide Fragments / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000378:metabolism; D010875:Pipecolic Acids / Q000494:pharmacology; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis; D018179:Receptors, Thrombin / Q000819:agonists*; D013449:Sulfonamides; D013917:Thrombin / Q000494:pharmacology*
D000991:Antithrombins; D007375:Interleukin-1; D007527:Isoenzymes; D010446:Peptide Fragments; D010716:Phosphatidylinositols; D010875:Pipecolic Acids; D018179:Receptors, Thrombin; D013449:Sulfonamides; C082835:thrombin receptor peptide (42-47); D001120:Arginine; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D013917:Thrombin; C031942:argatroban; D015232:Dinoprostone